Volga M 0.3/500 mg

Tablet for oral use. Take as advised by doctor, usually with meals; voglibose-containing combinations are commonly taken just before the main meals to control post-meal sugar. Swallow whole with water; do not skip meals. Dose is individualized based on blood glucose, kidney function and tolerance.

Voglibose inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate digestion and reducing post-meal blood glucose spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, increasing peripheral glucose uptake.

Not for type 1 diabetes or diabetic ketoacidosis. Metformin can rarely cause lactic acidosis—risk increases with kidney impairment, severe dehydration, sepsis, heavy alcohol use, liver disease, or hypoxia; monitor renal function before and during therapy. Use caution in elderly and in patients with heart failure. Temporarily stop metformin before/after iodinated contrast procedures or major surgery as advised. Voglibose may cause gastrointestinal discomfort; start/uptitrate gradually if needed. Monitor blood glucose and HbA1c regularly; hypoglycaemia risk increases if used with insulin or sulfonylureas.

Alcohol (increases lactic acidosis risk), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate/acetazolamide), cimetidine, ranolazine, dolutegravir, diuretics, corticosteroids, thyroid hormones, sympathomimetics, antipsychotics, insulin and sulfonylureas (increased hypoglycaemia risk when combined)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Voglibose 0.3 mg + Metformin 500 mg tablets (generic), Vobit-M 0.3/500, Volibo-M 0.3/500, Emvog-M 0.3/500, Voglib M 0.3/500